Artiva Biotherapeutics, Inc. (ARTV)

NASDAQ: ARTV · USD

$4.26

-0.01 (-0.3%)· Recorded snapshot

Market cap	208M
Net income (ttm)	-90.8M
EPS (ttm)	-$3.21
Shares out	48.9M
Volume	2,784,435
Beta	2.41

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -90.8M
EPS (ttm): -$3.21
Market cap: 208M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	احتفاظ

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-36.6

P25 n/aP50 n/aP75 n/a

ROIC-23.1

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All ARTV indicators

Market & fundamental data

Available fields

172

Groups with data

Currency

USD

Showing 172 of 172 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001817241
Company name	Artiva Biotherapeutics, Inc.
Country	United States
Country code	US
CUSIP number	04317A107
Earnings date	2026-11-11
Earnings time	bmo
Employees	115
Employees change	10
Employees growth	9.52%
Enterprise value	$-131.5M
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2019
In index	RUSSELL2000
Industry	Biotechnology
IPO date	2024-07-19
Is primary listing	Yes
Is SPAC	No
ISIN number	US04317A1079
Last 10-K release date	2026-03-10
Last earnings date	2026-08-06
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$208M
Market cap category	Micro-Cap
Next earnings date	2026-11-11
Options	Yes
Price	$4.26
Price currency	USD
Sector	Healthcare
SIC code	2836
Stock price date	2026-10-28
Symbol	ARTV
U.S. state	California
Website	https://www.artivabio.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-75.4%
FCF / EV yield	59.03%
FCF yield	-36.76%
P/B ratio	0.6x
Price / tangible book value	0.6x
Sector forward P/E	23.56x
Sector P/E	50.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Profit per employee	$-789,748
ROA	-22.34%
ROA (5Y)	-26.78%
ROCE	-27.16%
ROE	-36.58%
ROE (5Y)	-62.5%
ROIC	-23.13%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth quarters	1
EPS growth years	3
Net income growth years	0
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-1.7M
Depreciation and amortization	$2.7M
EBIT	$-96.1M
EBITDA	$-93.5M
EPS	$-3.21
FCF per share	$-1.57
Financing cash flow	$283M
Free cash flow	$-76.9M
Free cash flow minus SBC	$-83.6M
Investing cash flow	$65.2M
Net borrowing	$-111,000
Net cash flow	$273M
Net income	$-90.8M
Operating cash flow minus SBC	$-81.9M
Operating income	$-96.1M
Stock-based compensation	$6.7M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Book value per share	$7.12
Debt / equity	0.03
Long-term assets	$16.4M
Long-term liabilities	$6.6M
Net cash (debt)	$339.5M
Net cash / market cap	162.27%
Net cash growth	162.93%
Net debt / equity	-0.98
Piotroski F-Score	2
Property, plant and equipment	$15.1M
Shareholders' equity	$347.5M
Tangible book value	$347.5M
Tangible book value per share	$7.12
Total assets	$368.6M
Total cash	$349.4M
Total debt	$9.8M
Total liabilities	$21.1M
WACC	16.73%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current assets	$352.3M
Current liabilities	$14.6M
Current ratio	24.16
Net working capital	$-8.4M
Quick ratio	24.06
Working capital	$337.7M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-22.89%
Dividend yield	0%
Shareholder yield	-22.89%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$9.05
1D price change	-0.35%
1M price change	-38.56%
1M total return	-38.56%
1W price change	-34.53%
1W total return	-34.53%
1Y price change	-14.78%
1Y return CAGR	-14.79%
1Y total return	-14.78%
20-day SMA	$6.28
200-day SMA	$8.03
3M price change	-58.38%
3M total return	-58.38%
50-day SMA	$8.40
50-day SMA vs 200-day SMA	50over200
52-week high	$14.53
52-week high date	2026-04-20
52-week low	$2.96
52-week low date	2025-12-09
6M price change	-60.05%
6M total return	-60.05%
All-time high	$17.31
All-time high date	2024-10-01
All-time low	$1.47
All-time low date	2025-06-27
Average true range (ATR)	$0.54
Average volume	956.9K
Beta (1Y)	5.21
Beta (2Y)	2.74
Beta (5Y)	2.41
Change from 52-week high	-70.72%
Change from 52-week low	43.75%
Change from all-time high	-75.19%
Change from all-time low	192.18%
Change from open	-1.73%
Day's gap	1.41%
Dollar volume	$11.8M
High price	$4.36
Low price	$4.24
Monthly RSI	40.78
Open price	$4.33
Position in 52-week range	13.04%
Premarket change	2.11%
Premarket close	$4.27
Premarket price	$4.36
Premarket volume	29.7K
Previous close	$4.27
Price vs 150-day SMA	-52.56%
Price vs 20-day SMA	-31.64%
Price vs 200-day SMA	-46.51%
Price vs 50-day SMA	-48.88%
Relative volume	2.91
Return from IPO open	-73.25%
Return from IPO price	-64.33%
RSI	21.38
Sharpe ratio	0.45
Sortino ratio	0.9
Volume	2.8M
Weekly RSI	32.72
YTD price change	0.12%
YTD total return	0.12%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	19.5M
Float percentage	39.95%
Shares change (QoQ)	59.71%
Shares change (YoY)	22.89%
Shares held by insiders	4.64%
Shares held by institutions	40.64%
Shares outstanding	48.9M
Short % of float	11.76%
Short % of shares	4.7%
Short ratio	4.9 days

Deeper analysis on ARTV

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this ARTV report

Is a complete ARTV research report available?

No complete published report is available for Artiva Biotherapeutics, Inc. (ARTV) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Artiva Biotherapeutics, Inc. (ARTV)

Price

Financial snapshot

Fair-value bridge

Latest news · ARTV

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All ARTV indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on ARTV

Frequently asked questions